Limits...
Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer.

Ravi S, Singal AK - Core Evid (2014)

Bottom Line: In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options.Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC.Regorafenib, another multikinase inhibitor, has demonstrated inhibition of a broader range of kinases, along with higher inhibition potential in preclinical models.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

ABSTRACT
Hepatocellular carcinoma (HCC) is the second-most common cause of cancer-related death in the world. In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options. Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC. Over the last 5 years, several other medications have been tested in Phase III trials. However, they have not shown any added benefit over sorafenib. Regorafenib, another multikinase inhibitor, has demonstrated inhibition of a broader range of kinases, along with higher inhibition potential in preclinical models. After its safety and pharmacological properties was studied in Phase I trials, a Phase II study evaluating the role of Regorafenib in patients with advanced HCC who progressed on sorafenib therapy demonstrated efficacy and a manageable safety profile. A Phase III trial is ongoing, and its result will help us better evaluate the role of Regorafenib in patients with advanced HCC.

No MeSH data available.


Related in: MedlinePlus

Barcelona Clinic Liver Cancer staging system and treatment strategy.Note: Adapted from: This article was published in the Journal of Hepatology, 56, European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, 908-943, Copyright Elsevier 2012.2Abbreviations: RF, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, transcatheter arterial chemoembolization.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109634&req=5

f1-ce-9-081: Barcelona Clinic Liver Cancer staging system and treatment strategy.Note: Adapted from: This article was published in the Journal of Hepatology, 56, European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, 908-943, Copyright Elsevier 2012.2Abbreviations: RF, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, transcatheter arterial chemoembolization.

Mentions: Hepatocellular carcinoma (HCC) is the second-commonest cause of cancer-related death, and accounted for 746,000 world deaths in 2012. HCC is the fifth-commonest cancer in men and the ninth-commonest cancer in women, accounting for 782,000 new cases in 2012.1 Male sex and advancing age are common predisposing demographic factors, with the highest incidence rates reported from developing countries. Approximately 90% of HCC cases are associated with underlying chronic liver disease and liver cirrhosis, due to such risk factors as chronic hepatitis from hepatitis B and C virus infection, alcohol abuse, and aflatoxin exposure.2 Symptomatic tumors usually present at an advanced stage. In spite of regular screening and surveillance of patients at high risk for development of HCC, only about 30%–60% of cases can be diagnosed at a stage amenable to curative treatment options (Figure 1).3 In this review, we focus on the management of advanced HCC, especially the current status of Regorafenib, a multikinase inhibitor.


Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer.

Ravi S, Singal AK - Core Evid (2014)

Barcelona Clinic Liver Cancer staging system and treatment strategy.Note: Adapted from: This article was published in the Journal of Hepatology, 56, European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, 908-943, Copyright Elsevier 2012.2Abbreviations: RF, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, transcatheter arterial chemoembolization.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109634&req=5

f1-ce-9-081: Barcelona Clinic Liver Cancer staging system and treatment strategy.Note: Adapted from: This article was published in the Journal of Hepatology, 56, European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, 908-943, Copyright Elsevier 2012.2Abbreviations: RF, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, transcatheter arterial chemoembolization.
Mentions: Hepatocellular carcinoma (HCC) is the second-commonest cause of cancer-related death, and accounted for 746,000 world deaths in 2012. HCC is the fifth-commonest cancer in men and the ninth-commonest cancer in women, accounting for 782,000 new cases in 2012.1 Male sex and advancing age are common predisposing demographic factors, with the highest incidence rates reported from developing countries. Approximately 90% of HCC cases are associated with underlying chronic liver disease and liver cirrhosis, due to such risk factors as chronic hepatitis from hepatitis B and C virus infection, alcohol abuse, and aflatoxin exposure.2 Symptomatic tumors usually present at an advanced stage. In spite of regular screening and surveillance of patients at high risk for development of HCC, only about 30%–60% of cases can be diagnosed at a stage amenable to curative treatment options (Figure 1).3 In this review, we focus on the management of advanced HCC, especially the current status of Regorafenib, a multikinase inhibitor.

Bottom Line: In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options.Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC.Regorafenib, another multikinase inhibitor, has demonstrated inhibition of a broader range of kinases, along with higher inhibition potential in preclinical models.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

ABSTRACT
Hepatocellular carcinoma (HCC) is the second-most common cause of cancer-related death in the world. In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options. Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC. Over the last 5 years, several other medications have been tested in Phase III trials. However, they have not shown any added benefit over sorafenib. Regorafenib, another multikinase inhibitor, has demonstrated inhibition of a broader range of kinases, along with higher inhibition potential in preclinical models. After its safety and pharmacological properties was studied in Phase I trials, a Phase II study evaluating the role of Regorafenib in patients with advanced HCC who progressed on sorafenib therapy demonstrated efficacy and a manageable safety profile. A Phase III trial is ongoing, and its result will help us better evaluate the role of Regorafenib in patients with advanced HCC.

No MeSH data available.


Related in: MedlinePlus